Michelle Michels

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity

Andrew R. Harper, Anuj Goel, Christopher Grace et al. · Nature Genetics · 2021 · 339 citations · Full text

Medicine, Genetics, Molecular Genetics +14

Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy

Sabine J. van Dijk, Dennis Dooijes, Cristobal G. dos Remedios et al. · Circulation · 2009 · 330 citations · Full text

Medicine, Cardiology, Genetics +13

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy

Christopher N. Toepfer, Amanda C. Garfinkel, Gabriela Venturini et al. · Circulation · 2020 · 326 citations · Full text

Life Sciences, Cardiology, Molecular Biology +16

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron, Ahmad Masri, Michael E. Nassif et al. · New England Journal of Medicine · 2024 · 282 citations · Full text

Medicine, Cardiology, Pharmacotherapy +14